Literature DB >> 14871169

Drug-induced renal calculi: epidemiology, prevention and management.

Michel Daudon1, Paul Jungers.   

Abstract

Drug-induced calculi represent 1-2% of all renal calculi. The drugs reported to produce calculi formation may be divided into two groups. The first one includes poorly soluble drugs with high urine excretion that favours crystallisation in the urine. Among poorly soluble molecules, triamterene was the leading cause of drug-containing urinary calculi in the 1970s, and it is still currently responsible for a significant number of calculi. In the last decade, drugs used for the treatment of HIV-infected patients, namely indinavir and sulfadiazine, have become the most frequent cause of drug-containing urinary calculi. Besides these drugs, about twenty other molecules may induce nephrolithiasis in patients receiving long-term treatment or high doses. Calculi analysis by physical methods, including infrared spectroscopy or x-ray diffraction, is needed to demonstrate the presence of the drug or its metabolites within the calculi. The second group includes drugs that provoke urinary calculi as a consequence of their metabolic effects. Here, diagnosis relies on careful clinical inquiry because physical methods are ineffective to differentiate between urinary calculi induced by the metabolic effects of a drug and common metabolic calculi. The incidence of such calculi, especially those resulting from calcium/vitamin D supplementation, is probably underestimated. Although drug-induced urinary calculi most often complicate high-dose, long-duration drug treatments, there also exist specific patient risk factors in relation to urine pH, urine output and other parameters, which provide a basis for preventive or curative treatment of calculi. Better awareness of the possible occurrence of lithogenic complications, preventive measures based on drug solubility characteristics and close surveillance of patients on long-term treatment with drugs with lithogenic potential, especially those with a history of urolithiasis, should reduce the incidence of drug-induced nephrolithiasis.

Entities:  

Mesh:

Year:  2004        PMID: 14871169     DOI: 10.2165/00003495-200464030-00003

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  303 in total

1.  Urolithiasis in patients with end stage renal failure.

Authors:  M Daudon; B Lacour; P Jungers; T Drüeke; R J Reveillaud; A Chevalier; C A Bader
Journal:  J Urol       Date:  1992-04       Impact factor: 7.450

Review 2.  [Silicate urolithiasis: a case report].

Authors:  C Irisawa; K Suzuki; H Nakagawa; O Sugano; H Kato; Y Abe; M Ishigooka; N Ishii
Journal:  Hinyokika Kiyo       Date:  1991-03

3.  Renal alterations induced by sulfadiazine therapy in an AIDS patients.

Authors:  L P Marques; E P Madeira; O R Santos
Journal:  Clin Nephrol       Date:  1994-07       Impact factor: 0.975

4.  Reno-cerebral oxalosis induced by xylitol.

Authors:  B Ludwig; E Schindler; J Bohl; J Pfeiffer; G Kremer
Journal:  Neuroradiology       Date:  1984       Impact factor: 2.804

5.  Excretion of triamterene and its metabolite in triamterene stone patients.

Authors:  B Ettinger
Journal:  J Clin Pharmacol       Date:  1985 Jul-Aug       Impact factor: 3.126

6.  Triamterene-induced nephrolithiasis.

Authors:  R W Grunberg; S J Silberg
Journal:  JAMA       Date:  1981-06-26       Impact factor: 56.272

7.  Crystalluria and ciprofloxacin, influence of urinary pH and hydration.

Authors:  S B Thorsteinsson; T Bergan; S Oddsdottir; R Rohwedder; R Holm
Journal:  Chemotherapy       Date:  1986       Impact factor: 2.544

Review 8.  Crystalluria: a neglected aspect of urinary sediment analysis.

Authors:  G B Fogazzi
Journal:  Nephrol Dial Transplant       Date:  1996-02       Impact factor: 5.992

9.  Safety of topiramate: adverse events and relationships to dosing.

Authors:  S D Shorvon
Journal:  Epilepsia       Date:  1996       Impact factor: 5.864

10.  Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy.

Authors:  P S Venkataraman; B K Han; R C Tsang; C C Daugherty
Journal:  Am J Dis Child       Date:  1983-12
View more
  30 in total

Review 1.  Anecdotes that provide definitive evidence.

Authors:  Jeffrey K Aronson; Manfred Hauben
Journal:  BMJ       Date:  2006-12-16

2.  Efavirenz-induced urolithiasis.

Authors:  G J Wirth; J Teuscher; J D Graf; C E Iselin
Journal:  Urol Res       Date:  2006-04-20

3.  Gold standards in pharmacovigilance: the use of definitive anecdotal reports of adverse drug reactions as pure gold and high-grade ore.

Authors:  Manfred Hauben; Jeffrey K Aronson
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

Review 4.  Nephrolithiasis.

Authors:  Elaine M Worcester; Fredric L Coe
Journal:  Prim Care       Date:  2008-06       Impact factor: 2.907

5.  Medication-based urolithiasis and atazanavir.

Authors:  Paul M Koblic; Wayne L Gold; Charles J L la Porte; Todd C Lee
Journal:  CMAJ       Date:  2011-03-28       Impact factor: 8.262

6.  Synthesis and evaluation of oryzalin analogs against Toxoplasma gondii.

Authors:  Molla M Endeshaw; Catherine Li; Jessica de Leon; Ni Yao; Kirk Latibeaudiere; Kokku Premalatha; Naomi Morrissette; Karl A Werbovetz
Journal:  Bioorg Med Chem Lett       Date:  2010-07-08       Impact factor: 2.823

Review 7.  [Influence of drugs on urological diseases].

Authors:  P A Thürmann
Journal:  Urologe A       Date:  2016-03       Impact factor: 0.639

8.  Ceftriaxone associated urolithiasis in a child with hypercalciuria.

Authors:  V J Lozanovski; Z Gucev; V J Avramoski; I Kirovski; P Makreski; V Tasic
Journal:  Hippokratia       Date:  2011-04       Impact factor: 0.471

9.  Characterization of a sulfadiazine-induced lithiasis calculus by physicochemical techniques.

Authors:  C Cuervo; J González; V Rives; M A Vicente
Journal:  AAPS PharmSciTech       Date:  2012-12-14       Impact factor: 3.246

10.  Antibiotic Use and Risk of Incident Kidney Stones in Female Nurses.

Authors:  Pietro Manuel Ferraro; Gary C Curhan; Giovanni Gambaro; Eric N Taylor
Journal:  Am J Kidney Dis       Date:  2019-09-19       Impact factor: 8.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.